Baxalta Commences Phase 1 Clinical Trial of BAX 826, the Company’s Second Extended Half-Life Factor VIII Treatment for Hemophilia A

BANNOCKBURN, Ill.--(BUSINESS WIRE)--Baxalta Incorporated (NYSE:BXLT), a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, announced today that it has dosed the first patient in its Phase 1, first-in-human clinical trial of BAX 826, a recombinant Factor VIII (rFVIII) treatment for hemophilia A that uses proprietary polysialic acid (PSA) technology to extend its circulating half-life. BAX 826 is under investigation as Baxalta’s second extended half-life treatment based on ADVATE [Antihemophilic Factor (Recombinant)], the world's most prescribed FVIII treatment.